Total
0
Shares
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon
MD and CEO, Richard Carreon
Source: ImpediMed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ImpediMed (IPD) initiates its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago
  • ImpediMed says it has been able to leverage its existing footprint within the Advocate Aurora Health system to move forward with an initial heart failure program
  • Managing Director and CEO of ImpediMed Richard Carreon says after significant COVID-19 delays it is great to initiate the SOZO heart failure program at such a highly respected medical institution
  • ImpediMed shares are up 4.76 per cent, trading at 11 cents at 3:09 pm AEST

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    

AdvocateAuroraHealth, the conglomerate of Advocate Health Care in Illinois and Aurora Health Care in Wisconsin, is made up of 26 hospitals and more than 500 sites of care.

The introduction of SOZO is being championed by Ali Valika, an interventional cardiology specialist, with the aim of optimising fluid levels in heart failure patients, both in clinics and after discharge.

SOZO is a non-invasive bioimpedance spectroscopy device which can deliver a precise snapshot of fluid status and tissue composition in a patient in less than 30 seconds.

ImpediMed said it was able to leverage its existing footprint within the Advocate Aurora Health system to move forward with an initial heart failure program.

The Advocate Aurora Health system currently has 10 SOZO devices under a Lymphoedema Prevention Program.

Managing Director and CEO of ImpediMed Richard Carreon said after significant COVID-19 delays it was great to initiate the SOZO heart failure program at such a highly respected medical institution.

 “We are expecting other hospitals to initiate SOZO heart failure programs shortly, adding to the clinical and reimbursement evidence required to underpin widespread commercialisation,” Mr Carreon said.

ImpediMed shares were up 4.76 per cent, trading at 11 cents at 3:09 pm AEST.

IPD by the numbers
More From The Market Herald
Zelira Therapeutics (ASX:ZLD) - CEO and MD, Dr Oludare Odumosu

" Zelira Therapeutics (ASX:ZLD) recieves funding from Quincy Street

Zelira Therapeutics (ZLD) has raised US$5 million (around A$6.68) from US family office fund, Quincy Street Capital.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) pushes ahead with NASDAQ listing

Advanced Human Imaging (AHI) is pushing ahead with a planned NASDAQ listing, after filing a key form with the US Securities and Exchange
Opthea (ASX:OPT) - CEO and MD, Megan Baldwin

" Opthea (ASX:OPT) opens patient enrolment in Asia-Pacific

Opthea (OPT) has opened patient enrolment for its Phase 3 clinical program for the treatment of wet (neovascular) age-related macular degeneration (AMD) in

" TruScreen (ASX:TRU) highlights efficacy of cancer screening technology

TruScreen (TRU) says the results of a new study demonstrate its cervical cancer screening technology to be an effective alternative to other screening